Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 405 KB, PDF document
Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.
Translated title of the contribution | Management of non-alcoholic fatty liver disease |
---|---|
Original language | Danish |
Article number | V04220239 |
Journal | Ugeskrift for Laeger |
Volume | 184 |
Issue number | 42 |
Number of pages | 8 |
ISSN | 0041-5782 |
Publication status | Published - 2022 |
Links
ID: 326032542